Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$63.49
▼ $0.58 (-0.9%)
Market data updated: 09/17 10:20 AM
Fundamentals updated: 09/17/2026
News analyzed: 09/17/2026
Market Cap
$28.88B
Day Range
$63.28 - $64.46
52-Week Range
$58.75 - $89.77
Beta
—
Next Earnings
26.10.2026
GEHC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-18.1% (1Y)
Strengths: 2/29 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Return on equity (ROE)
Return on equity (ROE): 20.1% — strong
Fundamental
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
What to watch next
When today echoes the past.
75/100
Similarity
15
Historical Matches
89/100
Analog Quality
+6.8%
Median 40D Outcome
40/100
Pattern Consistency
🟢 Bullish
60%
+6.5% … +15.3%
🟡 Base
13%
+0.4% … +0.6%
🔴 Bearish
27%
-17.0% … -5.5%
Typical timeframe (based on real historical rates clearing a 60% bar): 10 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 60% (95% CI 36%–80%) saw the stock rise within 20 trading days, with a median gain of +5.9%.
Echo #1 — Oversold Reversal
1 occurrence(s) · 100% historical success
Echo #2 — Momentum Breakout
2 occurrence(s) · 100% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 53% (30%–75%) | +2.5% | -0.2% … +7.6% | -0.1% |
| 10D | 80% (55%–93%) | +5.3% | +1.3% … +6.9% | +0.1% |
| 20D | 60% (36%–80%) | +5.9% | -0.7% … +13.8% | +1.0% |
| 40D | 67% (42%–85%) | +6.8% | -6.9% … +19.4% | +1.3% |
| 60D | 67% (42%–85%) | +7.2% | -9.1% … +14.2% | +2.0% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2026-03-20 | 75/100 | Downtrend | +6.5% | -9.2% |
| 2025-03-14 | 73/100 | Downtrend | -23.4% | -9.8% |
| 2024-01-24 | 73/100 | Downtrend | +22.5% | +18.1% |
| 2024-06-07 | 70/100 | Consolidation | +0.7% | +14.7% |
| 2025-08-06 | 69/100 | Downtrend | +5.9% | +7.2% |
| 2023-10-26 | 69/100 | Downtrend | +15.3% | +12.0% |
| 2024-11-15 | 68/100 | Downtrend | -1.8% | +12.8% |
| 2025-11-17 | 67/100 | ✓ Downtrend | +16.5% | +13.7% |
| 2023-12-07 | 65/100 | Consolidation | +14.8% | +38.2% |
| 2025-03-28 | 65/100 | Downtrend | -14.9% | -9.1% |
| 2026-06-22 | 65/100 | Downtrend | +2.3% | +4.7% |
| 2024-12-19 | 63/100 | ✓ Downtrend | +12.8% | +5.7% |
| 2026-02-03 | 63/100 | Consolidation | +0.3% | -22.8% |
| 2026-04-28 | 62/100 | Downtrend | -6.7% | -11.6% |
| 2025-09-25 | 62/100 | Downtrend | +8.1% | +15.9% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
44
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
56
Quality
42
Value
55
Momentum
6
Risk
42
Sentiment
68
Fundamental
64
Institutional
100
Stocks with a similar DNA right now
SCANNING GEHC...
Recent media coverage of GE HealthCare has centered on its technological advancements and market expansion, particularly in medical imaging. The company is pursuing FDA clearance for its **StarGuide GX molecular imaging system**, aiming to revolutionize theranostics—a combined diagnostic and therapeutic approach. GE HealthCare also secured the **CE Mark for Photonova Spectra CT**, broadening its international presence. Additionally, partnerships like the one with **Tucker Medical in Singapore** highlight its focus on personalized preventive care. Stock analysis notes mixed market sentiment despite innovation.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about GE HealthCare. News trend score: 68. Reason: 5 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
36
Psychology
34
Fundamentals
64
Technical
6
Valuation
55
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+3%
Market Narrative
40
Fundamental Reality
36
Narrative Gap
+4
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **herding** is dominant, with GEHC trailing peers (-4.2% vs. -3.2%) today, indicating passive alignment rather than aggressive action. Low FOMO (score 2) and neutral volume (0.98x) imply limited urgency, while panic (25) is muted by subdued volatility (0.86x ATR). The key open question is whether this underperformance reflects a broader sector rotation or a localized liquidity event. Narrative-reality alignment (gap 0) suggests no mispricing narrative is driving the move.
Updated: 09/09/2026, 12:53 AM
What could change this?
👥 What the crowd believes
"GE Healthcare Technologies submits StarGuide GX for US FDA clearance (article 2)"
"GEHC wins CE Mark for Photonova Spectra, expanding internationally (article 6)"
"GE HealthCare unveils next-gen Vivid Cardiac Ultrasound Systems (article 11)"
"GEHC stock looks reasonable on earnings yet weak on market (article 5)"
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 98/100
🔴 Weakest match
Peter Lynch — 16/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between methodologies that prioritize cyclical positioning and those that demand strict valuation or defensive criteria. Samuel Armstrong Nelson and Charles Mackay’s high scores reflect their focus on market psychology and cycle timing—Nelson sees it as oversold, while Mackay detects no crowd-driven mania. In contrast, the Graham-based approaches (both Defensive and Enterprising Investor) and Fisher’s quality-focused model dismiss it outright, scoring poorly because the stock fails their margin-of-safety or growth-at-a-reasonable-price tests. Meanwhile, Marks’ mixed verdict highlights a tension between its cyclical appeal and potentially overpriced expectations, while Livermore and Bagehot’s low scores flag trend resistance and liquidity risks. The divide underscores whether the stock’s cyclical or psychological tailwinds outweigh its valuation or structural weaknesses.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 91
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 74
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 69
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 60
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 46
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 40
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 37
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 36
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 33
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 23
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 21
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 16
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
40.0%
Operating Margin
13.4%
Net Margin
10.1%
EBITDA Margin
13.4%
ROE
20.1%
ROA
5.6%
ROIC
—
EPS
$4.56
Cash
$4.49B
Total Debt
$10.00B
Current Ratio
1.37
Debt/Equity
0.96
אין נתונים היסטוריים זמינים.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 24.7.2026 | $0.035 |
| 23.7.2026 | $0.035 |
| 2.4.2026 | $0.035 |
| 1.4.2026 | $0.035 |
| 9.1.2026 | $0.035 |
| 8.1.2026 | $0.035 |
| 24.10.2025 | $0.035 |
| 23.10.2025 | $0.035 |
| 25.7.2025 | $0.035 |
| 24.7.2025 | $0.035 |
| 25.4.2025 | $0.035 |
| 24.4.2025 | $0.035 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$22.66
Tangible Book Value per Share (Tangible NAV)
-$9.26
Sentiment based on basic keywords (not AI) — 5 positive, 13 neutral, 2 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
MT Newswires · 15.9.2026
Yahoo · 15.9.2026
Business Wire · 15.9.2026
MT Newswires · 15.9.2026
MT Newswires · 14.9.2026
Benzinga · 14.9.2026
Benzinga · 13.9.2026
Barchart · 11.9.2026
Yahoo · 11.9.2026
MT Newswires · 10.9.2026
PR Newswire · 10.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
SeekingAlpha · 9.9.2026
Barrons.com · 8.9.2026
Yahoo · 8.9.2026
Yahoo · 8.9.2026
GE HealthCare (GEHC) currently has a StockIQ AI score of 44/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
GEHC currently scores 44/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
GEHC's technical score is 6/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Return on equity (ROE): 20.1% — strong; P/E: 14.0.
Based on the real signals StockIQ computed: Operating margin is eroding over time; Calmar: -0.04 (3y annualized return -1.4% / max drawdown 37.4%); Price is below the 50-day average.
Yes — GEHC has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Holton Adam Y | Tax Withholding in Shares | 3.9.2026 | 673 | -673 | $70.56 |
| Arduini Peter J | Tax Withholding in Shares | 3.9.2026 | 6,303 | -6,303 | $70.56 |
| O'Neill Kevin Michael | Tax Withholding in Shares | 3.9.2026 | 718 | -718 | $70.56 |
| Rackliffe Philip | Tax Withholding in Shares | 3.9.2026 | 798 | -798 | $70.56 |
| Kass-Hout Taha | Tax Withholding in Shares | 3.9.2026 | 1,502 | -1,502 | $70.56 |
| Jimenez Frank R | Tax Withholding in Shares | 3.9.2026 | 1,480 | -1,480 | $70.56 |
| Newcomb George A. | Tax Withholding in Shares | 3.9.2026 | 112 | -112 | $70.56 |
| Estrampes Catherine | Tax Withholding in Shares | 3.9.2026 | 508 | -508 | $70.56 |
| Rackliffe Philip | Tax Withholding in Shares | 1.9.2026 | 340 | -340 | $71.23 |
| Jimenez Frank R | Tax Withholding in Shares | 1.9.2026 | 1,380 | -1,380 | $71.23 |
| Holton Adam Y | Tax Withholding in Shares | 1.9.2026 | 659 | -659 | $71.23 |
| Bankes Jeannette | Tax Withholding in Shares | 1.9.2026 | 1,064 | -1,064 | $71.23 |
| Arduini Peter J | Tax Withholding in Shares | 1.9.2026 | 6,043 | -6,043 | $71.23 |
| Jimenez Frank R | Tax Withholding in Shares | 1.9.2026 | 1,751 | -1,751 | $71.23 |
| Kass-Hout Taha | Tax Withholding in Shares | 1.9.2026 | 1,296 | -1,296 | $71.23 |
| Kass-Hout Taha | Tax Withholding in Shares | 1.9.2026 | 1,644 | -1,644 | $71.23 |
| Arduini Peter J | Tax Withholding in Shares | 1.9.2026 | 5,472 | -5,472 | $71.23 |
| Rackliffe Philip | Tax Withholding in Shares | 1.9.2026 | 226 | -226 | $71.23 |
| Rackliffe Philip | Tax Withholding in Shares | 1.9.2026 | 290 | -290 | $71.23 |
| Holton Adam Y | Tax Withholding in Shares | 15.8.2026 | 1,360 | -1,360 | $73.69 |
| Lobo Kevin | Open Market Purchase | 22.5.2026 | 10,000 | +10,000 | $64.18 |
| Lobo Kevin | Open Market Purchase | 22.5.2026 | 14,363 | +10,000 | $64.18 |
| Bankes Jeannette | Tax Withholding in Shares | 15.5.2026 | 5,535 | -5,535 | $62.67 |
| Rackliffe Philip | Grant/Award from Employer | 15.5.2026 | 16,458 | +16,458 | — |
| Bankes Jeannette | Tax Withholding in Shares | 15.5.2026 | 38,357 | -5,535 | $62.67 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
18,955,374 shares short as of 2026-08-31 · vs. 19,385,482 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.8% of trading volume this week was short selling, vs. 59.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology